Systasy aims to deliver unmatched mode-of-action insight through highly multiplexed phenogenomic pathway profiling technologies for target selection, lead discovery and safety profiling. Its flagship technology, EXTassay, provides simultaneous analysis of multiple cellular and signalling events by utilizing molecularly barcoded reporters. The unmatched depth offered by this technology allows clients to decode target specificity and cellular effector profiles within one experiment.

In addition, Systasy’s proprietary splitSENSOR technology monitors and quantitatively measures cellular events such as regulated protein-protein interactions at the membrane and cytosol levels. Another unique value proposition of Systasy are extensive capabilities around human iPSC-based disease models. Combining the strength of these technologies allows to directly examine what´s going wrong in cells of patients suffering from complex diseases like brain disorders. Furthermore, their aptitude to provide integrated data on cell signalling through extensive parallel phenogenomic profiling technologies, thereby increasing in-depth mode-of-action knowledge are distinguished.